ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications
December 22, 2020 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Dec. 22, 2020 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema
December 15, 2020 01:15 ET
|
Novartis International AG
In Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52)1In a...
Ocugen Inc. Announces Plan to Postpone Annual Meeting of Stockholders
December 10, 2020 17:44 ET
|
Ocugen
MALVERN, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure...
Outlook on the Retinal Surgery Devices Global Market to 2025 - by Equipment Type, Application, End-use and Region
December 01, 2020 06:43 ET
|
Research and Markets
Dublin, Dec. 01, 2020 (GLOBE NEWSWIRE) -- The "Retinal Surgery Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy’s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell & Gene Therapies
November 27, 2020 08:09 ET
|
Ocugen
MALVERN, Pa., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure...
Global Wave-front Aberrometer Market Report 2020-2025: Companies are Taking Initiatives, Such as Launching New Products to Expand their Presence
November 26, 2020 06:13 ET
|
Research and Markets
Dublin, Nov. 26, 2020 (GLOBE NEWSWIRE) -- The "Wave-front Aberrometer Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. Myopia...
Cross Keys Capital Advises Retina Associates of Sarasota on Their Partnership with Retina Consultants of America
November 18, 2020 15:44 ET
|
Cross Keys Capital, LLC.
Fort Lauderdale, Florida, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Cross Keys Capital served as the exclusive M&A advisor to Retina Associates of Sarasota (RAS) in its partnership with Retina...
Graybug Vision to Participate in the 32nd Annual Piper Sandler Healthcare Conference
November 16, 2020 16:05 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
Clearside Biomedical Announces Data Presentations at the American Academy Ophthalmology (AAO) 2020 Annual Meeting and Publication on the Suprachoroidal Injection Procedure in Translational Vision Science and Technology
November 16, 2020 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
ProQR Announces Third Quarter 2020 Operating and Financial Results
November 16, 2020 07:00 ET
|
ProQR Therapeutics N.V.
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021Enrollment completed for QR-421a...